New mutations in TP53 gene drive resistance to p53-targeted cancer therapy

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...
The American Journal of Managed Care

Multi-Hit TP53 Mutations Linked With Poor Outcomes in MPN, AML

Multi-hit TP53 mutations are linked to poor survival in both MPN and AML, with median OS ranging from 4.8 to 11.6 months. Factors such as ASCT, pre-transplant therapy response, and concurrent TET2 or ...
News Medical

Researchers uncover why the TP53 gene is especially prone to mutations in cancer

In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...
ascopubs.org

Effect of co-occurring TP53 and intracellular proliferation pathway mutations on disease recurrence and survival benefits in head and neck cancers.

Dysphagia in cancers of the lip, oral cavity, and pharynx patients: Impact on cachexia, hospitalization, and racial disparities on outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Liquid biopsy advances could yield new tool for detecting lung cancer mutations

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...